Skip to main content

Advertisement

Articles

Page 1 of 15

  1. The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-be...

    Authors: Daria Bortolotti, Valentina Gentili, Antonella Rotola, Elisabetta Caselli and Roberta Rizzo

    Citation: Alzheimer's Research & Therapy 2019 11:104

    Content type: Research

    Published on:

  2. Since both APOE and ABCA7 protein expression may independently reduce neuritic plaque burden and reorganize fibrillar amyloid burden-mediated disruption of functional connectivity in the default mode network, we ...

    Authors: Ya-Ting Chang, Shih-Wei Hsu, Shu-Hua Huang, Chi-Wei Huang, Wen-Neng Chang, Chia-Yi Lien, Jun-Jun Lee, Chen-Chang Lee and Chiung-Chih Chang

    Citation: Alzheimer's Research & Therapy 2019 11:103

    Content type: Research

    Published on:

  3. EphA4 is a receptor of the ephrin system regulating spine morphology and plasticity in the brain. These processes are pivotal in the pathophysiology of Alzheimer’s disease (AD), characterized by synapse dysfun...

    Authors: Lindsay Poppe, Laura Rué, Mieke Timmers, Annette Lenaerts, Annet Storm, Zsuzsanna Callaerts-Vegh, Gilles Courtand, Antina de Boer, Silke Smolders, Philip Van Damme, Ludo Van Den Bosch, Rudi D’Hooge, Bart De Strooper, Wim Robberecht and Robin Lemmens

    Citation: Alzheimer's Research & Therapy 2019 11:102

    Content type: Research

    Published on:

  4. We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR...

    Authors: Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi-Saab, Mirjana Andjelkovic, Smiljana Ristic, Guoqiao Wang, Randall Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura and Rachelle Doody

    Citation: Alzheimer's Research & Therapy 2019 11:101

    Content type: Research

    Published on:

  5. Amyloid-β PET and CSF Aβ42 yield discordant results in 10–20% of memory clinic patients, possibly providing unique information. Although the predictive power of demographic, clinical, genetic, and imaging feature...

    Authors: Juhan Reimand, Arno de Wilde, Charlotte E. Teunissen, Marissa Zwan, Albert D. Windhorst, Ronald Boellaard, Frederik Barkhof, Wiesje M. van der Flier, Philip Scheltens, Bart N. M. van Berckel, Rik Ossenkoppele and Femke Bouwman

    Citation: Alzheimer's Research & Therapy 2019 11:100

    Content type: Research

    Published on:

  6. Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer’s disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within t...

    Authors: Anna Rosenberg, Alina Solomon, Vesna Jelic, Göran Hagman, Nenad Bogdanovic and Miia Kivipelto

    Citation: Alzheimer's Research & Therapy 2019 11:99

    Content type: Research

    Published on:

  7. Dementia has been presenting an imminent public health challenge worldwide. Studies have shown a combination of cognitive and physical trainings may have synergistic value for improving cognitive functions. Da...

    Authors: Lawla L. F. Law, Vincent C. T. Mok and Matthew M. K. Yau

    Citation: Alzheimer's Research & Therapy 2019 11:98

    Content type: Research

    Published on:

  8. Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglob...

    Authors: William J. Meilandt, Janice A. Maloney, Jose Imperio, Guita Lalehzadeh, Tim Earr, Susan Crowell, Travis W. Bainbridge, Yanmei Lu, James A. Ernst, Reina N. Fuji and Jasvinder K. Atwal

    Citation: Alzheimer's Research & Therapy 2019 11:97

    Content type: Research

    Published on:

  9. To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association...

    Authors: Virginia Pérez-Grijalba, Javier Arbizu, Judith Romero, Elena Prieto, Pedro Pesini, Leticia Sarasa, Fernando Guillen, Inmaculada Monleón, Itziar San-José, Pablo Martínez-Lage, Josep Munuera, Isabel Hernández, Mar Buendía, Oscar Sotolongo-Grau, Montserrat Alegret, Agustín Ruiz…

    Citation: Alzheimer's Research & Therapy 2019 11:96

    Content type: Research

    Published on:

  10. The development of diagnostic tools capable of accurately identifying the pathophysiology of mild cognitive impairment (MCI) has become a crucial target considering the claim that disease-modifying treatments ...

    Authors: Alessandro Padovani, Alberto Benussi, Maria Sofia Cotelli, Clarissa Ferrari, Valentina Cantoni, Valentina Dell’Era, Rosanna Turrone, Barbara Paghera and Barbara Borroni

    Citation: Alzheimer's Research & Therapy 2019 11:95

    Content type: Research

    Published on:

  11. Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and ne...

    Authors: Nicholas J. Ashton, Marc Suárez-Calvet, Amanda Heslegrave, Abdul Hye, Cristina Razquin, Pau Pastor, Raquel Sanchez-Valle, José L. Molinuevo, Pieter Jelle Visser, Kaj Blennow, Angela K. Hodges and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2019 11:94

    Content type: Research

    Published on:

  12. Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer’s disease (AD) on both the systemic and c...

    Authors: Vera van der Velpen, Tony Teav, Héctor Gallart-Ayala, Florence Mehl, Ioana Konz, Christopher Clark, Aikaterini Oikonomidi, Gwendoline Peyratout, Hugues Henry, Mauro Delorenzi, Julijana Ivanisevic and Julius Popp

    Citation: Alzheimer's Research & Therapy 2019 11:93

    Content type: Research

    Published on:

  13. Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early...

    Authors: Michelle M. Nuño, Daniel L. Gillen and Joshua D. Grill

    Citation: Alzheimer's Research & Therapy 2019 11:92

    Content type: Research

    Published on:

  14. Ongoing efforts within the Alzheimer’s disease (AD) field have focused on improving the intra- and inter-laboratory variability for cerebrospinal fluid (CSF) biomarkers. Fully automated assays offer the possib...

    Authors: Maria João Leitão, Anuschka Silva-Spínola, Isabel Santana, Veronica Olmedo, Alicia Nadal, Nathalie Le Bastard and Inês Baldeiras

    Citation: Alzheimer's Research & Therapy 2019 11:91

    Content type: Research

    Published on:

  15. It has been claimed that the retina can be used as a window to study brain disorders. However, concerning Alzheimer’s disease (AD), it still remains controversial whether changes occurring in the brain and ret...

    Authors: Samuel Chiquita, Elisa J. Campos, João Castelhano, Mário Ribeiro, José Sereno, Paula I. Moreira, Miguel Castelo-Branco and António Francisco Ambrósio

    Citation: Alzheimer's Research & Therapy 2019 11:90

    Content type: Research

    Published on:

  16. The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-β (OAβ) were affected in Alzheimer’s disease (AD) and to examine the associations (or possible correlations) bet...

    Authors: Xue Meng, Tao Li, Xiao Wang, Xiaozhen Lv, Zhiyu Sun, Jichun Zhang, Feng Su, Sungmin Kang, SangYun Kim, Seong Soo A. An, Xin Yu, Chen Zhang and Huali Wang

    Citation: Alzheimer's Research & Therapy 2019 11:89

    Content type: Research

    Published on:

  17. Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and...

    Authors: Dávid Nagy, Lauren Herl Martens, Liza Leventhal, Angela Chen, Craig Kelley, Milan Stoiljkovic and Mihály Hajós

    Citation: Alzheimer's Research & Therapy 2019 11:88

    Content type: Research

    Published on:

  18. Physical activity might reduce the risk of developing dementia. However, it is still unclear whether the protective effect differs depending on the subtype of dementia. We aimed to investigate if midlife physi...

    Authors: Oskar Hansson, Martina Svensson, Anna-Märta Gustavsson, Emelie Andersson, Yiyi Yang, Katarina Nägga, Ulf Hållmarker, Stefan James and Tomas Deierborg

    Citation: Alzheimer's Research & Therapy 2019 11:87

    Content type: Research

    Published on:

  19. Repeated failure of drug candidates targeting Alzheimer’s disease (AD) in clinical trials likely stems from a lack of understanding of the molecular mechanisms underlying AD pathogenesis. Recent research has h...

    Authors: Woo Shik Shin, Jing Di, Qin Cao, Binsen Li, Paul M. Seidler, Kevin A. Murray, Gal Bitan and Lin Jiang

    Citation: Alzheimer's Research & Therapy 2019 11:86

    Content type: Research

    Published on:

  20. Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study...

    Authors: Mary M. Ryan, Joshua D. Grill and Daniel L. Gillen

    Citation: Alzheimer's Research & Therapy 2019 11:85

    Content type: Research

    Published on:

  21. According to the 2018 NIA-AA research framework, Alzheimer’s disease (AD) is not defined by the clinical consequences of the disease, but by its underlying pathology, measured by biomarkers. Evidence of both a...

    Authors: Tiziana Carandini, Andrea Arighi, Luca Sacchi, Giorgio G. Fumagalli, Anna M. Pietroboni, Laura Ghezzi, Annalisa Colombi, Marta Scarioni, Chiara Fenoglio, Milena A. De Riz, Giorgio Marotta, Elio Scarpini and Daniela Galimberti

    Citation: Alzheimer's Research & Therapy 2019 11:84

    Content type: Research

    Published on:

  22. One of the major challenges in diagnosing dementia with Lewy bodies (DLB) is the common co-morbid presence of amyloid pathology. To understand the putative role of altered amyloid-β (Aβ) metabolism in dementia...

    Authors: Inger van Steenoven, Wiesje M. van der Flier, Philip Scheltens, Charlotte E. Teunissen and Afina W. Lemstra

    Citation: Alzheimer's Research & Therapy 2019 11:83

    Content type: Research

    Published on:

  23. Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer’s disea...

    Authors: Simon Sjödin, Gunnar Brinkmalm, Annika Öhrfelt, Lucilla Parnetti, Silvia Paciotti, Oskar Hansson, John Hardy, Kaj Blennow, Henrik Zetterberg and Ann Brinkmalm

    Citation: Alzheimer's Research & Therapy 2019 11:82

    Content type: Research

    Published on:

  24. We aimed to assess the relationship between levels of a cerebrospinal fluid (CSF) marker of pericyte damage, soluble platelet-derived growth factor receptor β (sPDGFRβ) and CSF markers of blood-brain barrier (...

    Authors: J. S. Miners, P. G. Kehoe, S. Love, H. Zetterberg and K. Blennow

    Citation: Alzheimer's Research & Therapy 2019 11:81

    Content type: Research

    Published on:

  25. Up to 20% of patients with AD experience hallucinations. The pathological substrate is not known. Visual hallucinations (VH) are more common in dementia with Lewy bodies (DLB). In autopsy studies, up to 60% of...

    Authors: Lindsey Isla Sinclair, Amit Kumar, Taher Darreh-Shori and Seth Love

    Citation: Alzheimer's Research & Therapy 2019 11:80

    Content type: Research

    Published on:

  26. Very little is known for the direction or causality of the relationship between lifetime sleep experiences and in vivo Alzheimer’s disease (AD) pathologies. This study aimed to examine the relationship between...

    Authors: Young Min Choe, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Bo Kyung Sohn, Yu Kyeong Kim, Seong A Shin, Chul-Ho Sohn, Yu Jin Lee and Dong Young Lee

    Citation: Alzheimer's Research & Therapy 2019 11:79

    Content type: Research

    Published on:

  27. In vivo, high cerebral amyloid-β load has been associated with (i) reduced concentrations of Aβ42 in cerebrospinal fluid and (ii) increased retention using amyloid-β positron emission tomography. Although these t...

    Authors: Arno de Wilde, Juhan Reimand, Charlotte E. Teunissen, Marissa Zwan, Albert D. Windhorst, Ronald Boellaard, Wiesje M. van der Flier, Philip Scheltens, Bart N. M. van Berckel, Femke Bouwman and Rik Ossenkoppele

    Citation: Alzheimer's Research & Therapy 2019 11:78

    Content type: Research

    Published on:

  28. Information given to patients and caregivers during the clinician-patient encounter varies considerably between memory clinic professionals. Patients and caregivers express a clear desire for more information....

    Authors: Agnetha D. Fruijtier, Leonie N. C. Visser, Ingrid S. van Maurik, Marissa D. Zwan, Femke H. Bouwman, Wiesje M. van der Flier and Ellen M. A. Smets

    Citation: Alzheimer's Research & Therapy 2019 11:77

    Content type: Research

    Published on:

  30. The lack of effective treatment options for Alzheimer’s disease (AD) is of momentous societal concern. Synaptic loss is the hallmark of AD that correlates best with impaired memory and occurs early in the dise...

    Authors: Joshua B. Foster, Rashelle Lashley, Fangli Zhao, Xueqin Wang, Nydia Kung, Candice C. Askwith, Lin Lin, Michael W. Shultis, Kevin J. Hodgetts and Chien-Liang Glenn Lin

    Citation: Alzheimer's Research & Therapy 2019 11:75

    Content type: Research

    Published on:

  31. The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was consider...

    Authors: Daniela Bertens, Stephanie Vos, Patrick Kehoe, Henrike Wolf, Flavio Nobili, Alexandre Mendonça, Ineke van Rossum, Jacub Hort, Jose Luis Molinuevo, Michael Heneka, Ron Petersen, Philip Scheltens and Pieter Jelle Visser

    Citation: Alzheimer's Research & Therapy 2019 11:74

    Content type: Research

    Published on:

  32. Mild cognitive impairment (MCI) among an aging global population is a growing challenge for healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate diagnosis ...

    Authors: Jeffrey Cummings, Peter Passmore, Bernadette McGuinness, Vincent Mok, Christopher Chen, Sebastiaan Engelborghs, Michael Woodward, Sagrario Manzano, Guillermo Garcia-Ribas, Stefano Cappa, Paulo Bertolucci and Leung-Wing Chu

    Citation: Alzheimer's Research & Therapy 2019 11:73

    Content type: Review

    Published on:

  33. Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been established as “AD signature”. To what e...

    Authors: Paula M. Petrone, Adrià Casamitjana, Carles Falcon, Miquel Artigues, Grégory Operto, Raffaele Cacciaglia, José Luis Molinuevo, Verónica Vilaplana and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2019 11:72

    Content type: Research

    Published on:

  34. Alzheimer’s disease (AD) is the most common form of dementia. This neurodegenerative disorder is associated with neuronal death and gliosis heavily impacting the cerebral cortex. AD has a substantial but heter...

    Authors: Jorge L. Del-Aguila, Zeran Li, Umber Dube, Kathie A. Mihindukulasuriya, John P. Budde, Maria Victoria Fernandez, Laura Ibanez, Joseph Bradley, Fengxian Wang, Kristy Bergmann, Richard Davenport, John C. Morris, David M. Holtzman, Richard J. Perrin, Bruno A. Benitez, Joseph Dougherty…

    Citation: Alzheimer's Research & Therapy 2019 11:71

    Content type: Research

    Published on:

  36. Alzheimer’s disease may compromise several musical competences, though no clear data is available in the scientific literature. Furthermore, music is capable of communicating basic emotions, but little is know...

    Authors: Eva M. Arroyo-Anlló, Stéphanie Dauphin, M. Noelle Fargeau, Pierre Ingrand and Roger Gil

    Citation: Alzheimer's Research & Therapy 2019 11:69

    Content type: Research

    Published on:

  37. Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assis...

    Authors: Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Christopher Lines and David Michelson

    Citation: Alzheimer's Research & Therapy 2019 11:68

    Content type: Research

    Published on:

  38. Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal mo...

    Authors: Matthias Brendel, Maximilian Deussing, Tanja Blume, Lena Kaiser, Federico Probst, Felix Overhoff, Finn Peters, Barbara von Ungern-Sternberg, Sergey Ryazanov, Andrei Leonov, Christian Griesinger, Andreas Zwergal, Johannes Levin, Peter Bartenstein, Igor Yakushev, Paul Cumming…

    Citation: Alzheimer's Research & Therapy 2019 11:67

    Content type: Research

    Published on:

  39. Subjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer’s disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with in...

    Authors: Lisa Miebach, Steffen Wolfsgruber, Alexandra Polcher, Oliver Peters, Felix Menne, Katja Luther, Enise Incesoy, Josef Priller, Eike Spruth, Slawek Altenstein, Katharina Buerger, Cihan Catak, Daniel Janowitz, Robert Perneczky, Julia Utecht, Christoph Laske…

    Citation: Alzheimer's Research & Therapy 2019 11:66

    Content type: Research

    Published on:

  40. Late-onset Alzheimer’s disease (AD) is characterized by primary memory impairment, which then progresses towards severe deficits across cognitive domains. Here, we report how performance in cognitive domains r...

    Authors: Leonardino A. Digma, John R. Madsen, Emilie T. Reas, Anders M. Dale, James B. Brewer and Sarah J. Banks

    Citation: Alzheimer's Research & Therapy 2019 11:65

    Content type: Research

    Published on:

  41. Longitudinal investigations are needed to improve understanding of the contributions of cerebral small vessel disease to the clinical manifestation of Alzheimer’s disease, particularly in the early disease sta...

    Authors: Christian Puzo, Caroline Labriola, Michael A. Sugarman, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Thor D. Stein, Neil W. Kowall, Ann C. McKee, Jesse Mez, Ronald J. Killiany, Robert A. Stern and Michael L. Alosco

    Citation: Alzheimer's Research & Therapy 2019 11:64

    Content type: Research

    Published on:

  43. Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer’s disease (AD). Retinal thinning is hypothesized to be a...

    Authors: Jurre den Haan, Lajos Csinscik, Tom Parker, Ross W. Paterson, Catherine F. Slattery, Alexander Foulkes, Femke H. Bouwman, Frank D. Verbraak, Philip Scheltens, Tunde Peto, Imre Lengyel, Jonathan M. Schott, Sebastian J. Crutch, Timothy J. Shakespeare and Keir X. X. Yong

    Citation: Alzheimer's Research & Therapy 2019 11:62

    Content type: Research

    Published on:

  44. Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer’s disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a m...

    Authors: Elizabeth Kuhn, Inès Moulinet, Audrey Perrotin, Renaud La Joie, Brigitte Landeau, Clémence Tomadesso, Alexandre Bejanin, Siya Sherif, Vincent De La Sayette, Béatrice Desgranges, Denis Vivien, Géraldine Poisnel and Gaëlle Chételat

    Citation: Alzheimer's Research & Therapy 2019 11:61

    Content type: Research

    Published on:

  45. Neuropathological studies have linked tau aggregates to neuronal loss. To describe the spatial distribution of neurofibrillary tangle pathology in post-mortem tissue, Braak staging has been used. The aim of th...

    Authors: Tessa Timmers, Rik Ossenkoppele, Emma E. Wolters, Sander C. J. Verfaillie, Denise Visser, Sandeep S. V. Golla, Frederik Barkhof, Philip Scheltens, Ronald Boellaard, Wiesje M. van der Flier and Bart N. M. van Berckel

    Citation: Alzheimer's Research & Therapy 2019 11:60

    Content type: Research

    Published on:

  46. The earliest brain pathology related to Alzheimer’s disease (AD) is hyperphosphorylated soluble tau in the noradrenergic locus coeruleus (LC) neurons. Braak characterizes five pretangle tau stages preceding AD...

    Authors: Abhinaba Ghosh, Sarah E. Torraville, Bandhan Mukherjee, Susan G. Walling, Gerard M. Martin, Carolyn W. Harley and Qi Yuan

    Citation: Alzheimer's Research & Therapy 2019 11:59

    Content type: Research

    Published on:

  47. Tau stabilizes microtubules; however, in Alzheimer’s disease (AD) and tauopathies, tau becomes hyperphosphorylated, aggregates, and results in neuronal death. Our group recently uncovered a unique interaction ...

    Authors: Leslie A. Sandusky-Beltran, Andrii Kovalenko, Chao Ma, John Ivan T. Calahatian, Devon S. Placides, Mallory D. Watler, Jerry B. Hunt, April L. Darling, Jeremy D. Baker, Laura J. Blair, Mackenzie D. Martin, Sarah N. Fontaine, Chad A. Dickey, April L. Lussier, Edwin J. Weeber, Maj-Linda B. Selenica…

    Citation: Alzheimer's Research & Therapy 2019 11:58

    Content type: Research

    Published on:

  48. Reduced 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer’s disease (AD) biolog...

    Authors: Ya-Nan Ou, Wei Xu, Jie-Qiong Li, Yu Guo, Mei Cui, Ke-Liang Chen, Yu-Yuan Huang, Qiang Dong, Lan Tan and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2019 11:57

    Content type: Research

    Published on:

  49. Intracerebral inoculation of extracts from post-mortem human Alzheimer’s disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the sy...

    Authors: Cristina M. Pedrero-Prieto, Alicia Flores-Cuadrado, Daniel Saiz-Sánchez, Isabel Úbeda-Bañón, Javier Frontiñán-Rubio, Francisco J. Alcaín, Lourdes Mateos-Hernández, José de la Fuente, Mario Durán-Prado, Margarita Villar, Alino Martínez-Marcos and Juan R. Peinado

    Citation: Alzheimer's Research & Therapy 2019 11:56

    Content type: Research

    Published on:

  50. Age-related frailty reflects cumulative multisystem physiological and health decline. Frailty increases the risk of adverse brain and cognitive outcomes, including differential decline and dementia. In a longi...

    Authors: Sherilyn Thibeau, Kirstie McDermott, G. Peggy McFall, Kenneth Rockwood and Roger A. Dixon

    Citation: Alzheimer's Research & Therapy 2019 11:55

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Advertisement

Alzheimer's Research & Therapy

ISSN: 1758-9193